Eight hundred and six patients were randomly assigned (2:1). Tumors were analyzed using the Myriad MyChoice HRD Plus assay to assess non–BRCA HRRm and HRD status; HRD was based on a genomic ...

A quality initiative focused on BRCA and HRD testing and use of first line maintenance in advanced ovarian cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium. This ...

“Therefore, BRCA -like status may serve as a predictive biomarker in this patient population. The benefits of the BRCA- like classifier include a lower dropout rate and a larger group of patients with ...

Homologous Recombination Deficiency (HRD) is a biomarker that enables the prediction of breast cancer treatment with first-line platinum-based chemotherapy or ovarian cancer treatment with PARP ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Testing to measure homologous repair deficiency (HRD) in certain cancers can identify patients who may benefit from poly(ADP-ribose) polymerase inhibitors. We examined real-world patterns and factors ...

Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors or breast cancer treatment with first-line platinum-based chemotherapy. However, ...

BARCELONA, Spain & MONTPELLIER, France--(BUSINESS WIRE)--SeqOne, provider of new generation genomic analysis solutions for personalized medicine, is announcing at the ESMO GYNAE conference a new HRD ...

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at ...

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive long-term follow-up results from the PAOLA-1 and SOLO-1 Phase III trials of LYNPARZA ® (olaparib), jointly developed and commercialized by AstraZeneca and ...

The presentation at Esmo of Tesaro’s (TSRO) ENGOT/Nova phase III trial of niraparib as maintenance therapy in ovarian cancer was one of the most eagerly anticipated at this year’s conference and, in ...